Visual Outcomes And Patient Satisfaction After Implantation Of The With A New Trifocal Intraocular Lens With Hydroxyethyl Methacrylate

The aim of our retrospective study is to evaluate the outcomes of the innovated trifocal IOL PanOptix Clareon both in toric and nontoric version. PanOptix trifocal IOL is well established on the market as a solution for patients seeking an increased level of spectacle independence. The combination with the Clareon material aims to improve the long term clarity of the IOL as well as the visual outcomes.

All patients have been treated at Ocni Klinika Zlin, Czech Republic. It is a private Eye Clinic.

Retrospective study of patients who underwent the cataract surgery with the implantation of the Clareon PanOptix trifocal IOL (toric and non-toric) from November 2023 to January 2024 with a 1-4 months follow up. Two surgeons, private clinic.

All patients had no underlying corneal or retinal pathologies, surgeries or glaucoma (evaluated by OCT, endothelial microscope and Pentacam/Corvis). Amblyopia with BCVA 0,7 and worse has been excluded. At 4-8 weeks distance, intermediate and near visual acuity has been evaluated. Patient- reported satisfaction as well as any complaints or complications, spectacle independence and visual disturbances have been recorded.

150 eyes of 77 patients have been included. Mean age 58 years. 60% women, 40% men. IOL Power from +13 to +34 dioptres. 62% have been hyperopic, 18% myopic and 20% emetropic. 2 eyes were midly amblyopic with BCVA 0,8. 51% had toric IOL (T2 to T5).

Postoperatively, 98% of eyes were within ± 1.00 D and 85 within ± 0.50 D of emmetropia. 95%, 97%, and 97% of patients achieved UDVA, UNVA, and UIVA of logMAR 0.1 or better.

Patients were generally satisfied with the outcome of the surgery. No major complains about visual disturbances. No spectacle prescription for driving or reading. Other complains were not connected to the IOL- increased eye sensitivity as our follow up period overlapped with the local epidemy of serious respiratory infections. 

Our clinic implants multifocal IOL for almost 20 years. PanOptix Clareon IOL seems to be very promising as it preserved the good visual acuity of AcrySof PanOptix and improved the clarity of the IOL. The new Monarch IV injector for Clareon improved the smoothness and safety of the surgery. Longer follow up is needed to asses neuroadaptation- at least 6 months.

It is always necessary to perform a complex evaluation of the patients to avoid those with pathologies or impossible expectations. For these patients Vivity or monofocal lenses may be a better option.